Press Releases

- 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 - - Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on November 30, 2017 - LONDON , Nov. 22, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on

Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program

LONDON and CARLSBAD, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.

- Morgan Stanley 15 th Annual Global Healthcare Conference on 13 September -             - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September - LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical

- Epidiolex ® NDA submission process underway -  - Conference call today at 4:30 p.m. EDT - LONDON and CARLSBAD, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and

LONDON, July 24, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its third

LONDON, June 07, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW management will

— Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control — — First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved

— Dr. Volker Knappertz appointed Chief Medical Officer — — Professor Ben Whalley to join as Head of Discovery Research — LONDON, May 15, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and

- Epidiolex ® NDA submission expected mid-year - - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology - - Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a